Nkarta, Inc.

Nkarta, Inc.

NKTX · Nasdaq

Nkarta, Inc. (NKTX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Nkarta, Inc. in 2026. The next earnings report is expected on November 11, 2026.

Earnings calendar

Next earnings date

11 Nov 2026

In 84 days

EPS estimate

-0.39

Revenue estimate

0

Past earnings

10 Aug 2026
EPS actual
-0.54 (-49.9%)
estimate -0.36
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
12 May 2026
EPS actual
-0.37 (-4.5%)
estimate -0.35
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
25 Mar 2026
EPS actual
-0.37 (-19.4%)
estimate -0.31
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
10 Nov 2025
EPS actual
-0.29 (+4.9%)
estimate -0.30
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Nkarta, Inc. missed consensus estimates on EPS, with EPS of $-0.54 versus an estimate of $-0.3603, while revenue met expectations at $0. In the prior quarter, EPS also missed estimates while revenue again met expectations.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
Nasdaq
CEO
Paul J. Hastings
Employees
157
IPO date
10 Jul 2020
ISIN
US65487U1088
Website
nkartatx.com

Frequently asked questions

When does Nkarta, Inc. (NKTX) next report earnings?

Nkarta, Inc. (NKTX) is scheduled to report earnings on November 11, 2026.

What was Nkarta, Inc.'s most recent earnings date?

Nkarta, Inc. (NKTX) last reported earnings on August 10, 2026.

Where is Nkarta, Inc. stock listed?

Nkarta, Inc. (NKTX) is listed on Nasdaq.